---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-013413"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-09-17T23:59:59+00:00"
generated_at: "2026-05-17T06:20:52.678106+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tonix in-licenses Phase 2/3-ready Lyme disease antibody TNX-4800

## Summary
- In-licensed worldwide rights to TNX-4800, a fully human monoclonal antibody targeting OspA of Borrelia burgdorferi.
- Designed as a single subcutaneous dose each Spring to protect against Lyme disease through Fall tick season.
- Positive Phase 1 study showed safety, tolerability, and linear PK/PD/efficacy relationship (1:1:1).
- Planning adaptive Phase 2/3 study; ~70 million people in U.S. endemic areas eligible for treatment.
- Developed by UMass Chan Medical School; no FDA-approved vaccines currently available for Lyme disease.

## SEC filing metadata
- accession: 0001999371-25-013413
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-09-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125013413/0001999371-25-013413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125013413/tnxp-8k_091725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-013413
- JSON: https://secwatch.observer/filing/0001999371-25-013413.json
- Plain text: https://secwatch.observer/filing/0001999371-25-013413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.